ArticlePediatric surgery international2008
Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone.
Article in Pediatric surgery international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Transcatheter Ductus Arteriosus Stenting for Acute Pediatric Pulmonary Arterial Hypertension is Associated with Improved Right Ventricular Echocardiography Strain.Pediatric cardiology · 2024Article
- Prostaglandin-E1 infusion in persistent pulmonary hypertension of the newborn.Pediatric pulmonology · 2024Article
- Use of Prostaglandin E1 in the Management of Congenital Diaphragmatic Hernia-A Review.Frontiers in pediatrics · 2022Review
- Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm.European journal of pediatrics · 2021Review
- Congenital diaphragmatic hernia: a narrative review of controversies in neonatal management.Translational pediatrics · 2021Review
- Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates.The Cochrane database of systematic reviews · 2019Review
- Congenital Diaphragmatic hernia - a review.Maternal health, neonatology and perinatology · 2017Review
- Current Concepts in the Management of Congenital Diaphragmatic Hernia in Infants.The Indian journal of surgery · 2015Review
- Management Practice and Mortality for Infants with Congenital Diaphragmatic Hernia.American journal of perinatology · 2015Article
- Persistent pulmonary hypertension of the newborn.Maternal health, neonatology and perinatology · 2015Article
- Initial oxygenation response to inhaled nitric oxide predicts improved outcome in congenital diaphragmatic hernia.Drugs in R&D · 2014Article
- Antenatal use of bosentan and/or sildenafil attenuates pulmonary features in rats with congenital diaphragmatic hernia.World journal of pediatrics : WJP · 2014Article
- Pulmonary artery size has prognostic value in low birth weight infants with congenital diaphragmatic hernia.Pediatric surgery international · 2011Article
- Recent advances in the management of congenital diaphragmatic hernia.Indian journal of pediatrics · 2010Article
- Significance of pulmonary artery size and blood flow as a predictor of outcome in congenital diaphragmatic hernia.Pediatric surgery international · 2008Article
- Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants.Expert opinion on pharmacotherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimProstaglandin-E1 (PGE1) is used at most centers for treating pulmonary hypertension (PH) in congenital diaphragmatic hernia (CDH) because it has been regarded as effective. The aim of this study was to investigate the role of PGE1 for treating PH in CDH.
methodsWe reviewed 49 CDH cases with echocardiography-proven PH. PH was treated with PGE1 and nitric oxide (NO) and high frequency oscillatory ventilation (HFOV) from 1997 to 2001 (PG + NO; n = 19) and with NO and HFOV from 2002 to 2007 (NO; n = 30).
resultsSubject demographics, severity of PH, and presence of other anomalies were not significantly different between the two groups. In the PG + NO group, 12/19 (63.2%) survived (PG + NO-s) and 7/19 (36.8%) died (PG + NO-d). In the NO group, 21/30 (70.0%) survived (NO-s) and 9/30 (30.0%) died (NO-d). Survival rates were not significantly different. In the NO-s group, spontaneous closure of the ductus arteriosus (DA) was significantly earlier compared with the PG + NO-s group (P < 0.01; 4.0 +/- 0.9 vs. 9.5 +/- 2.2 days after birth). DA diameters were significantly larger in groups that died compared with groups that survived (P < 0.01), and PH persisted in groups that died. In the NO-s group, surgery was possible significantly earlier compared with the PG + NO-s group (P < 0.01; 3.75 +/- 0.67 vs. 6.12 +/- 0.78 days after birth). No NO-s case developed a PH crisis even though PGE1 was not used. Hospital stay was significantly shorter in the NO-s group compared with the PG + NO-s group (P < 0.05; 39.9 +/- 19 vs. 53.2 +/- 23 days).
conclusionNitric oxide alone would appear to simplify the management of CDH with PH and provide better outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.